[en] Forty-six previously untreated patients with advanced breast cancer were eligible for the present randomised phase I study. It aimed to evaluate the toxicity and activity of a therapeutic sequence with epirubicin on day 1 followed by paclitaxel on day 2 (sequence A) or the reverse sequence, ie., paclitaxel on day 1 followed by epirubicin on day 2 (sequence B). The starting doses of epirubicin and paclitaxel, administered either according to sequence A or B, (level 1 cohort) were 90 mg/m2 and 175 mg/m2, respectively. Per cohort of 3 patients, the dose of paclitaxel was increased by 25 mg/m2 (levels 2 and 4) and of epirubicin by 10 mg/m2 (levels 3 and 5). Treatment was repeated with 3-week intervals. The maximal tolerated dose (MTD) was achieved at level 1 in sequence B (paclitaxel first) and level 3 (epirubicin 100 mg/m2 followed by paclitaxel 200 mg m2) in sequence A. Dose limiting toxicity (DLT) was neutropenia (+/- febrile) in both sequences. Cardiac events occurred in 28% of the patients; significant decrease in left ventricular ejection function (LVEF) was observed in 8/33 and in 2/13 patients in sequence A and B, respectively. This was associated with 5 and 1 cardiac heart failure (CHF), respectively. In 43 evaluable patients, 10 CR and 25 PR were observed (overall response rate 81%). In the 20 patients with locally advanced disease (LABC), the respective numbers were 7 CR and 11 PR; in the 23 metastatic (MBC) patients, 3 CR and 14 PR were recorded. The median survival of the both groups was not reached at 33 + months. In conclusion , the combination of epirubicin and paclitaxel has significant activity in breast cancer. The recommended sequence of both drugs in combination therapy, mainly to avoid neutropenia, is epirubicin day 1 followed by paclitaxel on day 2. Cardiac toxicity remains problematic in either sequence of administration.
Disciplines :
Oncology
Author, co-author :
Focan, C.
Graas, M. P.
Beauduin, M.
Canon, J. L.
Salmon, J.-P.
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Focan-Henrard, D.
Lobelle, J. P.
Schallier, D.
Language :
English
Title :
Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Del Mastro, L., Sormani, M., Venturini, M., Tumor response as surrogate end-point for survival in metastatic breast cancer patients: A meta-analysis (2005) J Clin Oncol, , in press
Greenberg, P.A.C., Hortobagyi, G.N., Smith, T.L., Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer (1996) J Clin Oncol, 14, pp. 2197-2205
Gluck, S., The expanding role of epirubicin in the treatment of breast cancer (2002) Cancer Control, 9 (2 SUPPL.), pp. 16-27
Ormrod, D., Holm, K., Goa, K., Epirubicin: A review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer (1999) Drugs Aging, 15, pp. 389-416
Focan, C., Andrien, J.M., Closon, M.T., Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial (1993) J Clin Oncol, 11, pp. 1253-1263
Di Leo, A., Piccart, M.J., Paclitaxel activity, dose, and schedule: Data from phase III trials in metastatic breast cancer (1999) Semin Oncol, 26 (3 SUPPL. 8), pp. 27-32
Nabholtz, J.M., Reese, D.M., Lindsay, M.A., Docetaxel in the treatment of breast cancer: An update on recent studies (2002) Semin Oncol, 29, pp. 28-34
Nabholtz, J.M., Gelman, K., Bontenbal, M., Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer (1996) J Clin Oncol, 14, pp. 1858-1867
Sledge Jr., G.W., Robert, N., Sparano, J.A., Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience (1994) Semin Oncol, 5 (21 SUPPL. 8), pp. 15-18
Berg, S.L., Cowan, K.H., Balis, F.K., Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion (1994) J Natl Cancer Inst, 86, pp. 143-145
Holmes, F.A., Valero, V., Walters, R.S., Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results (1999) Ann Oncol, 10, pp. 403-411
Conte, P.F., Baldini, E., Gennari, A., Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer (1997) J Clin Oncol, 15, pp. 2510-2517
Gianni, L., Munzone, E., Capri, G., Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study (1995) J Clin Oncol, 13, pp. 688-699
Gianni, L., Dombernowsky, P., Sledge, G., Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer (2001) Ann Oncol, 12, pp. 1067-1073
Dent, S.F., Eisenhauer, E.A., Phase I trial design: Are new methodologies being put into practice? (1996) Ann Oncol, 7, pp. 561-566
Akutsu, M., Kano, Y., Tsunoda, S., Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro (1995) Eur J. Cancer, 31 A, pp. 2341-2346
Frassineti, G.I., Zoli, W., Tienghi, A., The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer (1996) Semin Oncol, 23 (5 SUPPL. 12), pp. 22-28
Hahn, S.M., Liebmann, J.E., Cook, J., Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro (1993) Cancer, 72, pp. 2705-2711
Koechli, O.R., Sevin, B.U., Perras, J.P., Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay (1993) Breast Cancer Res Treat, 28, pp. 21-27
Konecny, G., Untch, M., Slamon, D., Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples (2001) Breast Cancer Res Treat, 67, pp. 223-233
Viallet, J., Tsao, M.S., Gallant, G., Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines (1996) Lung Cancer, 15, pp. 93-101
Colombo, T., Parisi, I., Zucchetti, M., Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin (1999) Ann Oncol, 10, pp. 391-395
Grasselli, G., Vigano, L., Capri, G., Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer (2001) J Clin Oncol, 19, pp. 2222-2231
Holmes, F.A., Rowinsky, E.K., Pharmacokinetic profiles of doxorubicin in combination with taxanes (2001) Semin Oncol, 28, pp. 8-14
Danesi, R., Innocenti, G., Fogli, S., Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients (2002) Br J Clin Pharmacol, 53, pp. 508-518
Razis, E.D., Fountzilas, G., Paclitaxel: Epirubicin in metastatic breast cancer - A review (2001) Ann Oncol, 12, pp. 593-598
Venturini, M., Lunardi, G., Del Mastro, L., Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity (2000) J Clin Oncol, 18, pp. 2116-2125
Moreira, A., Lobato, R., Morais, J., Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer (2001) Cancer Chemother Pharmacol, 48, pp. 333-337
Minotti, G., Saponiero, A., Licata, S., Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium (2001) Clin Cancer Res, 7, pp. 1511-1515
Esposito, M., Venturini, M., Vannozzi, M.O., Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients (1999) J Clin Oncol, 17, pp. 1132-1140
Rischin, D., Webster, L.K., Millward, M.J., Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel (1996) J Natl Cancer Inst, 88, pp. 1297-1301
Webster, L.K., Cosson, E.J., Stokes, K.H., Effect of the paclitaxel vehicle, cremophor EL, on the phamacokinetics of doxorubicin and doxorubicinol in mice (1996) Br J Cancer, 73, pp. 522-524
Sparano, J.A., Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations (1998) Semin Oncol, 25 (4 SUPPL. 10), pp. 66-71
Luck, H.J., Thomssen, C., Untch, M., Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group (2000) Proc Am Soc Clin Oncol, 19, pp. 73a. , abstr 280
Biganzoli, L., Cufer, T., Bruning, P., Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial (2002) J Clin Oncol, 20, pp. 3114-3121
Carmichael, J., UKCCR trial of epirubicin and cyclophosphamide (EC) vs epirubicin and taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC) (2001) Proc Am Soc Clin Oncol, 20, pp. 22a. , abstr 84
Jassem, J., Pienkowski, T., Pluzanska, A., Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial (2001) J Clin Oncol, 19, pp. 1707-1715
